Generex Biotechnology Corporation GNBT OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

26/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Generex Biotechnology Corporation (GNBT) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 24/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

26/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

25/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

35/100

→ Income

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — GNBT

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.02

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.46

Book Value / Share$0.00

Revenue / Share$0.04

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2011	$-2.59	$291.63K	$-21.68M	-7432.8%
2012	$-0.97	$28.65K	$-9.49M	-33122.8%
2013	$-0.66	$0.00	$-8.55M	-
2014	$0.00	$0.00	$-1.42K	-
2015	$-0.09	$0.00	$-2.19M	-
2016	$-0.12	$0.00	$-3.22M	-
2017	$-2.41	$0.00	$-70.02M	-
2018	$0.48	$703.24K	$36.33M	5166.6%
2019	$-0.14	$6.2M	$-9.34M	-150.6%
2020	$-0.46	$2.66M	$-33.34M	-1252.7%